MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia
暂无分享,去创建一个
G. Tomlinson | B. A. Hirschman | R. Swinney | S. Hsu | T. Chen | T. Chen
[1] K. Kelsey,et al. CYP1A1 variants and smoking‐related lung cancer in San Francisco bay area Latinos and African Americans , 2005, International journal of cancer.
[2] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[3] L. Clegg,et al. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. , 2002, Medical and pediatric oncology.
[4] B. Christensson,et al. MDM2 AND p53 IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: Higher Expression in Childhood Leukemias with Poor Prognosis Compared to Long-Term Survivors , 2001, Pediatric hematology and oncology.
[5] E. Lukhtanov,et al. 3'-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. , 2000, Nucleic acids research.
[6] M. Spitz,et al. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[7] J. Shuster,et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Bartram,et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. , 1993, Blood.